DaVita (DVA) Stock Price, News & Analysis

DaVita Inc. (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is a comprehensive kidney care provider and has been described in its own disclosures as a leader in clinical quality and innovation for 25 years. DaVita operates in the kidney dialysis centers industry within the broader health care and social assistance sector and its common stock is listed on the New York Stock Exchange under the ticker symbol DVA.

According to multiple company statements, DaVita cares for patients at every stage and setting along their kidney health journey. This includes efforts to slow the progression of kidney disease, support transplantation, provide acute hospital care, and deliver dialysis at home and in outpatient centers. The company reports that it has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to encourage the kidney care community to adopt a higher quality standard of care for patients with kidney disease.

Global kidney care footprint

DaVita reports serving hundreds of thousands of patients worldwide through a large network of outpatient dialysis centers. As of March 31, 2025, the company stated that it served approximately 282,000 patients at 3,173 outpatient dialysis centers, with 2,661 centers in the United States and 512 centers in 13 other countries. Later disclosures noted growth to approximately 283,100 patients at 3,175 centers as of June 30, 2025, and approximately 293,200 patients at 3,247 centers as of September 30, 2025, including 2,662 centers in the United States and 585 centers in 14 other countries. These figures illustrate the scale of DaVita’s operations in kidney care.

In addition to in-center dialysis, DaVita’s descriptions emphasize care across multiple settings, including hospital-based services and home dialysis. The company also highlights its role in supporting kidney transplantation, both through research and through care models that aim to increase transplant access for eligible patients.

Integrated kidney care and value-based models

DaVita describes itself as a participant in integrated kidney care and value-based care arrangements. The company has stated that, together with participating nephrologists, it launched 11 value-based care arrangements in 2022 and later expanded this footprint to 22 Kidney Contracting Entities under the government’s Kidney Care Choices (KCC) Model. A company statement attributes to these arrangements outcomes such as increased transplantation, more patients dialyzing with an optimal access in place, and more patients dialyzing at home.

DaVita also reports operating integrated kidney care (IKC) programs that manage medical spend for patients in risk-based arrangements. As of June 30, 2025, the company stated that it had approximately 64,400 patients in risk-based integrated care arrangements, representing an estimated annualized medical spend, and an additional group of patients in other integrated care arrangements. As of September 30, 2025, DaVita reported approximately 64,900 patients in risk-based integrated care arrangements, again with additional patients in other integrated care programs. These disclosures underscore the company’s focus on coordinated care and financial risk-sharing models in kidney disease management.

Clinical research and innovation focus

DaVita frequently highlights its research activities and commitment to advancing kidney treatment through data-driven insights. At the American Society of Nephrology’s Kidney Week 2025, DaVita Clinical Research presented multiple studies addressing topics such as dialysis treatments, middle molecule clearance, access to transplantation, and end-of-life care for patients with end-stage kidney disease. One oral presentation examined the association between GLP-1 receptor agonist use and hospitalization rates in patients with end-stage kidney disease.

The company has also announced initiatives focused on middle-molecule clearance in dialysis. Two programs, referred to as MODEL and MEMOIRS, are designed to evaluate the use of medium cut-off dialyzers and compare patient outcomes and experiences with different dialyzer types. DaVita describes these efforts as intended to generate U.S.-based evidence on how removal of larger waste molecules during dialysis may affect clinical outcomes and quality of life for adults living with kidney failure.

Business scale and financial profile

DaVita’s public financial disclosures show that it generates substantial revenue from its kidney care operations. For the quarters ended June 30, 2025 and September 30, 2025, the company reported consolidated revenues in the billions of dollars, along with operating income and cash flow figures that reflect a large-scale health care enterprise. The company also reports regular share repurchases under a board-authorized repurchase program and has disclosed amendments to its senior secured credit facilities, including term loans and revolving credit facilities arranged with a syndicate of lenders.

In an 8-K filing dated November 24, 2025, DaVita described an Eighth Amendment to its credit agreement that provides a new secured term loan A facility and a new secured revolving credit facility. The company stated that proceeds from these facilities are intended to refinance prior term and revolving facilities, pay related fees and expenses, and support working capital and general corporate purposes, which may include stock repurchases, acquisitions and investments.

Corporate governance and leadership context

DaVita’s governance structure includes a board of directors, and public information notes that at least one director, Gregory J. Moore, MD, PhD, serves on DaVita’s board while also being involved in other health and technology initiatives. Company news releases also describe appointments to senior leadership roles, such as a Chief People Officer and Chief Strategy Officer, emphasizing experience in health care sectors including providers, medical devices and pharmaceuticals, and a focus on strategy, culture and growth in kidney care and chronic disease management.

Through its communications, DaVita emphasizes a people-centered approach to care delivery, highlighting the role of its teammates, physician partners and nephrologists in delivering dialysis services, advancing research and implementing integrated care models. The company’s disclosures also reference efforts to respond to evolving technologies, cybersecurity considerations and regulatory programs that shape the kidney care environment.

Regulatory status and exchange listing

SEC filings confirm that DaVita Inc. is incorporated in Delaware and that its common stock, with a stated par value, is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the symbol DVA. The company files current reports on Form 8-K related to financial results, share repurchase authorizations and credit facility amendments, among other matters. These filings, together with press releases, provide investors and analysts with information on DaVita’s operations, capital structure and strategic initiatives.